iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology
▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.i...
iNtRON, Executes Evaluation License and Option Agreement for SAL200
* iNtRON Grants Basilea exclusive right for preclinical evaluation with an undisclosed payment * Basilea has the option to enter into exclusive License Agreement following the evaluation BOSTON and SEOUL, South Korea, Oct. 30, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",www.intodeworl...
iNtRON identifies Prophage and Jamphage in the Pancreatic cancer related Microbiome
* It was confirmed the presence of Prophage and Jamphage in the Alkalihalobacillus clausii * Prophage and Jamphage are expected to play a substantial role in bacterial survival and immune regulation in the body. BOSTON and SEOUL, South Korea, May 29, 2023 /PRNewswire/ -- iNtRON Biotechnology ...
iNtRON confirms cancer-controlling effect of PHAGERIA® drug candidate in the organoid model.
* Secured the effectiveness confirming data of PHAGERIA® technology for colorectal cancer organoids * The first target cancer type of PHAGERIA® technology is colorectal cancer (CRC) BOSTON and SEOUL, South Korea, April 3, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",www.intodeworld.com...
iNtRON has confirmed the efficacy of BAL200, a novel endolysin biologic for Inhalational Anthrax
* Confirmed antibacterial efficacy against a variety of anthrax strains including the one used in the 2001 anthrax attack * Provides the most potent bactericidal ability that no other PEP antibiotics in the market can exhibit * Further developments are planned to conduct with a licensing/col...
iNtRON is finalizing the SAL200 Tech Transfer
* Including the contract transfers of the external studies planned for the
successful out-licensing and commercialization of SAL200 BOSTON and SEOUL,
South Korea, Jan. 11, 2023 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",
www.intodeworld.com
iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis
* The transposon technology development following the customized CRISPR/Cas
system for bacteriophage
* 2nd Generation technology of Robot Bacteriophage BOSTON and SEOUL, South
Korea, Oct. 17, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON",
www.intodeworld.com
iNtRON developed New CRISPR/Cas technology specific for Bacteriophage as PHAGERUS® Platform
* CRISPR/Cas system for bacteria that are not E. coli or Streptococcus pyogenes * Customized gene editing technology for unique modified-bacteriophages * To validate efficacy of SARS-CoV-2 mimotopes loaded PHAGERUS® platform BOSTON and SEOUL, South Korea, Aug. 9, 2022 /PRNewswire/ -- iNtRON ...
iNtRON Confirms Efficacy of CDL200 Against CDI Clinical Isolates
* Shows potent and rapid antibacterial activity against clinical isolates in Europe and Korea both * CDL200, a novel endolysin pipeline for the treatment of Clostridioides difficile Infection (CDI) * The world's first endolysin in capsule formulation to be administered orally BOSTON and SEO...
iNtRON to Seek a New Clinical Partner for SAL200 Endolysin
* TONABACASE, the first registered INN by WHO for Endolysin * First-in-Class Endolysin-based Drug against Superbugs * US FDA Phase 2 IND Approval for TONABACASE, SAL200 * Roivant has returned the rights for the asset just before the first patient injection BOSTON and SEOUL, South Korea, Jun...
iNtRON Completes GLP-TOX Studies of BAL200
* A novel drug candidate for anthrax received orphan drug designation (ODD) by the US FDA. BOSTON and SEOUL, Korea, June 6, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON" or "Company") announced today that the company has successfully completed the GLP toxicology studies of BAL200. The co...
iNtRON Biotechnology, Inc., Launches New Website
It aims to promote strategic collaborations in global while also highlights its many innovative advances and successful scientific ventures. BOSTON and SEOUL, South Korea, May 9, 2022 /PRNewswire/ -- The parent company of iNtODEWORLD, Inc., iNtRON Biotechnology, Inc., ("iNtRON" or "Company") is ...
